Trial Profile
A Phase 1 Study in Healthy Volunteers to Investigate Possible Interactions Between RG1662 and Midazolam
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Basmisanil (Primary) ; Midazolam; Midazolam
- Indications Down syndrome
- Focus Pharmacokinetics
- Sponsors Roche
- 13 May 2016 The time frame of the PK endpoints have changed from Up to 9 weeks to "re-dose [-0.5 hour (h)] and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 14 h post-dose (pd) on Day (D) 2 and 18, and 22 h pd on D3 and 19"
- 26 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Oct 2014 New trial record